Why it matters now
The global pharmaceutical industry heavily relies on India and China for the supply of active pharmaceutical ingredients (APIs). While cost-effective, this concentration creates significant vulnerabilities to geopolitical tensions, trade disputes, natural disasters, or manufacturing disruptions. Understanding which specific molecules are most exposed to this concentration risk is crucial for ensuring drug supply continuity and mitigating potential shortages.
Who is exposed
Pharmaceutical manufacturers, especially generic drug companies, face significant supply chain disruption risks, potentially leading to drug shortages and revenue losses. API suppliers in these regions are exposed to policy changes and demand shifts. Patients could experience critical medication shortages. Regulatory bodies are concerned about national drug security and the resilience of essential medicine supplies.
Most relevant for: Chief Procurement Officer, Head of Supply Chain, Risk Management Director
What this Viewpoint covers
- Which essential drug molecules have a high dependency on API sourcing from India?
- Which essential drug molecules have a high dependency on API sourcing from China?
- How do regulatory filings reveal the geographic origin of specific APIs?
- What are the alternative sourcing options or manufacturing capabilities for high-risk APIs?
- How do geopolitical developments influence the stability of API supply from these regions?
Signals to watch
- Changes in trade policies or export restrictions from India or China.
- Announcements of new API manufacturing facilities in other regions.
- Reports of quality control issues or environmental shutdowns impacting API production.
- Strategic partnerships forming to diversify API supply chains.
Decisions it supports
- Supply chain risk assessment and mitigation strategies.
- Diversification of API sourcing locations.
- Investment in internal API manufacturing capabilities.
- Strategic inventory management for critical drug products.
How it is built
Prepared after your order from dated public sources - such as pharma & biotech filings and announcements, regulatory records, trials, patents and trade data, where relevant - and our market model. Reported facts are cited, estimates are labelled and our assessment is marked as such, following our research method. You receive our verdict, the evidence, who is exposed, the signals to watch and recommended actions, within 24 hours.
Questions
What is API sourcing concentration risk?
API sourcing concentration risk refers to the vulnerability of the pharmaceutical supply chain when a large proportion of a specific active pharmaceutical ingredient (API) comes from a limited number of geographic regions or suppliers, particularly from India and China. Any disruption in these regions can severely impact global drug availability.
Why is this risk important for pharmaceutical companies?
For pharmaceutical companies, this risk can lead to critical drug shortages, production delays, increased costs, and regulatory non-compliance. It threatens business continuity and can have severe public health consequences if essential medicines become unavailable. Proactive management of this risk is vital for resilience.
How can companies reduce this concentration risk?
Companies can reduce concentration risk by diversifying their API supplier base across multiple countries, investing in redundant manufacturing capabilities, or exploring domestic or nearshore production options. Strategic partnerships, long-term contracts, and maintaining buffer inventories for critical APIs also contribute to a more resilient supply chain.